SG11202007471WA - Granzyme b directed imaging and therapy - Google Patents

Granzyme b directed imaging and therapy

Info

Publication number
SG11202007471WA
SG11202007471WA SG11202007471WA SG11202007471WA SG11202007471WA SG 11202007471W A SG11202007471W A SG 11202007471WA SG 11202007471W A SG11202007471W A SG 11202007471WA SG 11202007471W A SG11202007471W A SG 11202007471WA SG 11202007471W A SG11202007471W A SG 11202007471WA
Authority
SG
Singapore
Prior art keywords
granzyme
therapy
directed imaging
imaging
directed
Prior art date
Application number
SG11202007471WA
Inventor
Geoffrey Bilcer
Terence Kelly
Original Assignee
Cytosite Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytosite Biopharma Inc filed Critical Cytosite Biopharma Inc
Publication of SG11202007471WA publication Critical patent/SG11202007471WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03Computed tomography [CT]
    • A61B6/037Emission tomography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202007471WA 2018-02-13 2019-02-13 Granzyme b directed imaging and therapy SG11202007471WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862629949P 2018-02-13 2018-02-13
US201862724433P 2018-08-29 2018-08-29
PCT/US2019/017802 WO2019160916A1 (en) 2018-02-13 2019-02-13 Granzyme b directed imaging and therapy

Publications (1)

Publication Number Publication Date
SG11202007471WA true SG11202007471WA (en) 2020-09-29

Family

ID=67619639

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007471WA SG11202007471WA (en) 2018-02-13 2019-02-13 Granzyme b directed imaging and therapy

Country Status (10)

Country Link
US (2) US11667645B2 (en)
EP (1) EP3752145A4 (en)
JP (1) JP2021512964A (en)
KR (1) KR20200120712A (en)
CN (1) CN112261939A (en)
AU (1) AU2019220633A1 (en)
CA (1) CA3091016A1 (en)
MX (1) MX2020008408A (en)
SG (1) SG11202007471WA (en)
WO (1) WO2019160916A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019220633A1 (en) 2018-02-13 2020-08-27 Cytosite Biopharma Inc. Granzyme B directed imaging and therapy
EP3924354A1 (en) * 2019-02-13 2021-12-22 Cytosite Biopharma Inc. Granzyme b directed imaging and therapy
CN113512090A (en) * 2021-04-30 2021-10-19 复旦大学附属肿瘤医院 Granzyme B binding compound, precursor compound thereof and application
CN116589527B (en) * 2023-04-25 2023-12-12 北京大学第一医院 Granzyme B targeted inhibitor, nuclear medicine probe and application

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002245649A1 (en) * 2001-03-02 2002-09-19 Idun Pharmaceuticals, Inc. Methods, compositions and kits for preserving antigenicity
JP2005522430A (en) * 2002-02-04 2005-07-28 メルク エンド カムパニー インコーポレーテッド Granzyme B inhibitor
WO2006017295A2 (en) * 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
EP2648735A4 (en) * 2010-12-06 2014-07-30 Univ British Columbia Granzyme b inhibitor compositions, methods and uses for promoting wound healing
WO2014139014A1 (en) * 2013-03-15 2014-09-18 The University Of British Columbia Methods and compositions for the inhibition of vascular endothelial growth factor activity and vascular permeability
US9605021B2 (en) * 2013-03-29 2017-03-28 Vida Therapeutics Inc. Indoline compounds as granzyme B inhibitors
WO2018005926A1 (en) * 2016-07-01 2018-01-04 The General Hospital Corporation Granzyme b directed imaging and therapy
AU2019220633A1 (en) 2018-02-13 2020-08-27 Cytosite Biopharma Inc. Granzyme B directed imaging and therapy

Also Published As

Publication number Publication date
MX2020008408A (en) 2020-10-28
AU2019220633A1 (en) 2020-08-27
WO2019160916A1 (en) 2019-08-22
CA3091016A1 (en) 2019-08-22
US20200369673A1 (en) 2020-11-26
EP3752145A1 (en) 2020-12-23
KR20200120712A (en) 2020-10-21
US20230257388A1 (en) 2023-08-17
CN112261939A (en) 2021-01-22
US11667645B2 (en) 2023-06-06
JP2021512964A (en) 2021-05-20
EP3752145A4 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
EP3478162A4 (en) Granzyme b directed imaging and therapy
SG11202007471WA (en) Granzyme b directed imaging and therapy
IL283511A (en) Dendrimer for therapy and imaging
GB201807410D0 (en) Diagnostic method and therapy
GB201713284D0 (en) Therapy and diagnostics
GB201814040D0 (en) Testing and therapy
GB201812388D0 (en) Therapeutic and diagnostic target
GB201804219D0 (en) Therapeutic and diagnostic target
GB201804127D0 (en) Therapeutic and diagnostic target
GB201804125D0 (en) Therapeutic and diagnostic target
GB201804126D0 (en) Therapeutic and diagnostic target
GB201803925D0 (en) Therapeutic and diagnostic target
GB201803921D0 (en) Therapeutic and diagnostic target
GB201803934D0 (en) Therapeutic and diagnostic target
GB201803830D0 (en) Therapeutic and diagnostic target
GB201803840D0 (en) Therapeutic and diagnostic target
GB201803374D0 (en) Therapeutic and diagnostic target
GB201720788D0 (en) Therapeutic and diagnostic target
GB201806133D0 (en) Methods and medical uses
GB201716948D0 (en) Therapeutic and diagnostic target
GB201716947D0 (en) Therapeutic and diagnostic target
GB201716945D0 (en) Therapeutic and diagnostic target
GB201716949D0 (en) Therapeutic and diagnostic target
GB201712533D0 (en) Therapeutic and diagnostic target
IL257210A (en) System and